Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by McEvoy, J. P. Search for Related Content PubMed Citation Articles by McEvoy, J. P. Schizophrenia Spectrum Disorders Atypical Neuroleptics Conventional Neuroleptics Related Article

Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

OBJECTIVE: When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine. In this study, the authors compared switching to clozapine with switching to another atypical antipsychotic in patients who had discontinued treatment with a newer atypical antipsychotic in the context of the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation. METHOD: Ninety-nine patients who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily because of inadequate efficacy, were randomly assigned to open-label treatment with clozapine (N=49) or blinded treatment with another newer atypical antipsychotic not previously received in the trial (olanzapine [N=19], quetiapine [N=15], or risperidone [N=16]). RESULTS: Time until treatment discontinuation for any reason was significantly longer for clozapine (median=10.5 months) than for quetiapine (median=3.3), or risperidone (median=2.8), but not for olanzapine (median=2.7). Time to discontinuation because of inadequate therapeutic effect was significantly longer for clozapine than for olanzapine, quetiapine, or risperidone. At 3-month assessments, Positive and Negative Syndrome Scale total scores had decreased more in patients treated with clozapine than in patients treated with quetiapine or risperidone but not olanzapine. One patient treated with clozapine developed agranulocytosis, and another developed eosinophilia; both required treatment discontinuation. CONCLUSIONS: For these patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypical antipsychotic. Safety monitoring is necessary to detect and manage clozapine’s serious side effects.

Related Article:

In This Issue
Am J Psychiatry 2006 163: A50. [Full Text] [PDF]

This article has been cited by other articles:

				A. Sparshatt, E. Whiskey, and D. Taylor Valproate as prophylaxis for clozapine-induced seizures: survey of practice Psychiatr. Bull., July 1, 2008; 32(7): 262 - 265. [Abstract] [Full Text] [PDF]

				A. J Wheeler Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand Ann. Pharmacother., June 1, 2008; 42(6): 852 - 860. [Abstract] [Full Text] [PDF]

				L. Citrome, A. Jaffe, D. Martello, B. Allingham, and J. Levine Datapoints: Did CATIE Influence Antipsychotic Use? Psychiatr Serv, May 1, 2008; 59(5): 476 - 476. [Full Text] [PDF]

				N. H. Covell, M. T. Finnerty, and S. M. Essock Implications of CATIE for Mental Health Services Researchers Psychiatr Serv, May 1, 2008; 59(5): 526 - 529. [Abstract] [Full Text] [PDF]

				J. J. Parks, A. Q. Radke, and R. Tandon Impact of the CATIE Findings on State Mental Health Policy Psychiatr Serv, May 1, 2008; 59(5): 534 - 536. [Abstract] [Full Text] [PDF]

				C. U. Correll, C. Rummel-Kluge, C. Corves, J. M. Kane, and S. Leucht Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials Schizophr Bull, April 21, 2008; (2008) sbn018v2. [Abstract] [Full Text] [PDF]

				J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment Schizophr Bull, April 2, 2008; (2008) sbn019v1. [Abstract] [Full Text] [PDF]

				M. J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T. I. Cremers, J.-M. Rivet, D. Sicard, R. Billiras, and M. Brocco S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1212 - 1226. [Abstract] [Full Text] [PDF]

				J. M. Kane and S. Leucht Unanswered Questions in Schizophrenia Clinical Trials Schizophr Bull, March 1, 2008; 34(2): 302 - 309. [Full Text] [PDF]

				T. S. Stroup and J. R. Geddes Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals Schizophr Bull, March 1, 2008; 34(2): 266 - 274. [Abstract] [Full Text] [PDF]

				S. Lewis and J. Lieberman CATIE and CUtLASS: can we handle the truth? The British Journal of Psychiatry, March 1, 2008; 192(3): 161 - 163. [Abstract] [Full Text] [PDF]

				Bibliography Schizophrenia Focus, January 1, 2008; 6(2): 197 - 199. [Full Text] [PDF]

				Abstracts Focus, January 1, 2008; 6(2): 200 - 204. [Full Text] [PDF]

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Focus, January 1, 2008; 6(2): 212 - 220. [Abstract] [Full Text] [PDF]

				E. C. Kutscher, G. P. Robbins, W. K. Kennedy, K. Zebb, M. Stanley, and R. M. Carnahan Clozapine-induced leukopenia successfully treated with lithium Am. J. Health Syst. Pharm., October 1, 2007; 64(19): 2027 - 2031. [Abstract] [Full Text] [PDF]

				D. L. Kelly, J. Kreyenbuhl, L. Dixon, R. C. Love, D. Medoff, and R. R. Conley Clozapine Underutilization and Discontinuation in African Americans Due to Leucopenia Schizophr Bull, September 1, 2007; 33(5): 1221 - 1224. [Abstract] [Full Text] [PDF]

				L. R. Gardell, K. E. Vanover, L. Pounds, R. W. Johnson, R. Barido, G. T. Anderson, I. Veinbergs, A. Dyssegaard, P. Brunmark, A. Tabatabaei, et al. ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 862 - 870. [Abstract] [Full Text] [PDF]

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Psychiatr Serv, July 1, 2007; 58(7): 983 - 990. [Abstract] [Full Text] [PDF]

				J. P. McEvoy, J. A. Lieberman, D. O. Perkins, R. M. Hamer, H. Gu, A. Lazarus, D. Sweitzer, C. Olexy, P. Weiden, and S. D. Strakowski Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison Am J Psychiatry, July 1, 2007; 164(7): 1050 - 1060. [Abstract] [Full Text] [PDF]

				C. A. Tamminga and J. M. Davis The Neuropharmacology of Psychosis Schizophr Bull, July 1, 2007; 33(4): 937 - 946. [Abstract] [Full Text] [PDF]

				S. G. Leckband, J. R. Bishop, and V. L. Ellingrod Pharmacogenomics in Psychiatry Journal of Pharmacy Practice, June 1, 2007; 20(3): 252 - 264. [Abstract] [PDF]

				R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al. Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial Arch Gen Psychiatry, June 1, 2007; 64(6): 633 - 647. [Abstract] [Full Text] [PDF]

				L. Eisenberg Furor Therapeuticus: Benjamin Rush and the Philadelphia Yellow Fever Epidemic of 1793 Am J Psychiatry, April 1, 2007; 164(4): 552 - 555. [Full Text] [PDF]

				S. R. Marder Lessons From Each Drug Trial Am J Psychiatry, March 1, 2007; 164(3): 375 - 376. [Full Text] [PDF]

				T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, G. A. Capuano, R. A. Rosenheck, R. S.E. Keefe, A. L. Miller, I. Belz, et al. Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study Am J Psychiatry, March 1, 2007; 164(3): 415 - 427. [Abstract] [Full Text] [PDF]

				S. Bleakley, O. Olofinjana, and D. Taylor Which antipsychotics would mental health professionals take themselves? Psychiatr. Bull., March 1, 2007; 31(3): 94 - 96. [Abstract] [Full Text] [PDF]

				S. M. Essock, N. H. Covell, S. M. Davis, T. S. Stroup, R. A. Rosenheck, and J. A. Lieberman Effectiveness of Switching Antipsychotic Medications Am J Psychiatry, December 1, 2006; 163(12): 2090 - 2095. [Abstract] [Full Text] [PDF]

				J. A. Lieberman Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry, October 1, 2006; 63(10): 1069 - 1072. [Full Text] [PDF]

				L. A. Opler The American Psychiatric Publishing Textbook of Schizophrenia JAMA, June 28, 2006; 295(24): 2892 - 2893. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us